In the BioHarmony Drug Report Database
Symlin (pramlintide) is a protein pharmaceutical. Pramlintide was first approved as Symlin on 2005-03-16. It is used to treat type 1 diabetes mellitus and type 2 diabetes mellitus in the USA. It is known to target calcitonin receptor.
Image (chem structure or protein)